Enliven Therapeutics (ELVN) Amortizatization of Intangibles (2019 - 2026)
Enliven Therapeutics (ELVN) reported Amortizatization of Intangibles of -$266000.0 for Q1 2026, down 691.11% on a YoY basis from $45000.0 in Q1 2025, and down 383.64% sequentially from -$55000.0 in Q4 2025.
Enliven Therapeutics (ELVN) Amortizatization of Intangibles (2019 - 2026) Analysis & Trends
Enliven Therapeutics (ELVN) has 8 years of Amortizatization of Intangibles data on file, last reported at -$266000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles fell 691.11% year-over-year to -$266000.0; the trailing twelve-month figure through Mar 2026 stood at -$84000.0 (up 91.92% YoY), and the FY2025 full-year result was $227000.0, up 153.54% from the prior year.
- Amortizatization of Intangibles fell to -$266000.0 in Q1 2026, from -$55000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $2.0 million in Q3 2023 to a low of -$976000.0 in Q4 2024.
- A 5-year average of $295714.3 and a median of $46500.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles surged 1631.25% in 2023 and sank 691.11% in 2026, its largest moves.
- Tracing ELVN's Amortizatization of Intangibles over 5 years: stood at $48000.0 in 2022, then surged by 3625.0% to $1.8 million in 2023, then plunged by 154.59% to -$976000.0 in 2024, then jumped by 94.36% to -$55000.0 in 2025, then sank by 383.64% to -$266000.0 in 2026.
- Business Quant data shows ELVN's Amortizatization of Intangibles at -$266000.0 in Q1 2026, -$55000.0 in Q4 2025, and $310000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Enliven Therapeutics | 3.33 Bn | 2.88 Bn | - | -266,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -266,000.00 |
| Mar 31, 2026 | -266,000.00 |
| Dec 31, 2025 | -55,000.00 |
| Dec 31, 2025 | -55,000.00 |
| Sep 30, 2025 | 310,000.00 |
| Sep 30, 2025 | 310,000.00 |
| Jun 30, 2025 | -73,000.00 |
| Jun 30, 2025 | -73,000.00 |
| Mar 31, 2025 | 45,000.00 |
| Mar 31, 2025 | 45,000.00 |
| Dec 31, 2024 | -976,000.00 |
| Dec 31, 2024 | -976,000.00 |
| Sep 30, 2024 | -712,000.00 |
| Sep 30, 2024 | -712,000.00 |
| Jun 30, 2024 | 603,000.00 |
| Jun 30, 2024 | 603,000.00 |
| Mar 31, 2024 | 661,000.00 |
| Mar 31, 2024 | 661,000.00 |
| Dec 31, 2023 | 1.79 Mn |
| Dec 31, 2023 | 1.79 Mn |